According to findings of a study published in JAMA, a bioresorbable occluder has been shown to be noninferior to traditional ...

Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...

Three months of clopidogrel given on top of aspirin was associated with a reduced frequency of migraine in patients who had undergone transcatheter closure of an atrial septal defect (ASD) in the ...

While rare, infective endocarditis is a devastating complication after device closure of atrial septal defects (ASDs), and much remains unknown about when infections begin and how clinicians can best ...

Long-term survival after transcatheter closure of secundum atrial septal defects (ASD) is similar to that achieved after surgical closure, but the former method is far more likely to require ...

FRANKFURT, GERMANY--(Marketwired - July 22, 2016) - Nobles Medical Technologies II (NMT2) continued to surprise the more than 900 cardiologist and cardiac-specialist attendees at the CSI conference on ...

LOS ANGELES, CA--(Marketwired - March 10, 2016) - Dr. Niels Erik Nielsen, Director of Structural Heart Interventions at the Linkoping University Hospital in Linkoping Sweden, successfully performed ...

Overall, there was a 15.8% incidence of migraines in the first 3 months following the procedure among people randomized to clopidogrel (Plavix) plus aspirin or aspirin alone. After this initial period ...